CRISPR Therapeutics AG, headquartered in Zug, develops gene-based medicines for serious diseases using its CRISPR/Cas9 platform and went public on October 19, 2016. The company focuses on gene editing to treat genetically-defined diseases and enhance cellular therapies.
CRSP has been in the news recently: CRISPR Therapeutics AG is involved in the development of gene-editing therapies, and its technology has been successfully applied in a case at the Children's Hospital of Philadelphia, where a child with a rare metabolic disease was treated using customized CRISPR therapy. This achievement highlights the potential of CRISPR-based treatments in addressing complex medical conditions.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
